Opinion

Video

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Chronic Lymphocytic Leukemia | Image Credit: © LAZLO - stock.adobe.com
April 25th 2025

Orelabrutinib Wins Approval in China for First-Line CLL and SLL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Multiple Myeloma | Image Credit: © Mikkel – stock.adobe.com
April 24th 2025

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Chronic Lymphocytic Leukemia | Image Credit: © ivlianna – stock.adobe.com
April 16th 2025

MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.
April 13th 2025

Five Under 5: Top Oncology Videos for the Week of 4/6